LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome

[1]  J. Tyson,et al.  Endocrine resistance in breast cancer – An overview and update , 2015, Molecular and Cellular Endocrinology.

[2]  M. Bentires-Alj,et al.  Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy. , 2015, Molecular cell.

[3]  Wei Gao,et al.  Hsa-miR-301a-3p Acts as an Oncogene in Laryngeal Squamous Cell Carcinoma via Target Regulation of Smad4 , 2015, Journal of Cancer.

[4]  Shu-peng Chen,et al.  MiR-449a suppresses the epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma by multiple targets , 2015, BMC Cancer.

[5]  M. Hou,et al.  The Immune Regulator VTCN1 Gene Polymorphisms and Its Impact on Susceptibility to Breast Cancer , 2015, Journal of clinical laboratory analysis.

[6]  Yonglei Liu,et al.  miR-449a promotes liver cancer cell apoptosis by downregulation of Calpain 6 and POU2F1 , 2015, Oncotarget.

[7]  M. Todaro,et al.  miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance , 2015, Cell Death and Disease.

[8]  M. Dowsett,et al.  Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Ellis,et al.  Mechanisms of aromatase inhibitor resistance , 2015, Nature Reviews Cancer.

[10]  Michael G. Kharas,et al.  PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer , 2015, Science Translational Medicine.

[11]  Wenxin Qin,et al.  LRG1 suppresses the migration and invasion of hepatocellular carcinoma cells , 2015, Medical Oncology.

[12]  N. Urban,et al.  Validation of LRG1 as a Potential Biomarker for Detection of Epithelial Ovarian Cancer by a Blinded Study , 2015, PloS one.

[13]  Guangshun Wang,et al.  非小细胞肺癌患者尿蛋白质组差异表达分析 , 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[14]  M. Sussman,et al.  The Concentrations of EGFR, LRG1, ITIH4, and F5 in Serum Correlate with the Number of Colonic Adenomas in ApcPirc/+ Rats , 2014, Cancer Prevention Research.

[15]  Jaana M. Hartikainen,et al.  Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium , 2014, Human molecular genetics.

[16]  E. Diamandis,et al.  Deciphering the peptidome of urine from ovarian cancer patients and healthy controls , 2014, Clinical Proteomics.

[17]  W. Xu,et al.  LRG1 is an independent prognostic factor for endometrial carcinoma , 2014, Tumor Biology.

[18]  Lei Wang,et al.  Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling. , 2014, Gene.

[19]  J. Foekens,et al.  Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer. , 2013, Cancer research.

[20]  Andrea Sottoriva,et al.  The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.

[21]  S. Sleijfer,et al.  Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen , 2013, Breast Cancer Research and Treatment.

[22]  Stefano Volinia,et al.  Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer , 2013, Proceedings of the National Academy of Sciences.

[23]  M. Dowsett,et al.  Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance , 2013, Clinical Cancer Research.

[24]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[25]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[26]  N. Traficante,et al.  The Australian Ovarian Cancer Study , 2012, Hereditary Cancer in Clinical Practice.

[27]  Carme Camps,et al.  microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.

[28]  W. Miller,et al.  Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole , 2010, Breast Cancer Research.

[29]  Paul Ellis,et al.  PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.

[30]  K. Nakayama,et al.  Phospholipase C-related but Catalytically Inactive Protein Is Required for Insulin-induced Cell Surface Expression of γ-Aminobutyric Acid Type A Receptors* , 2009, The Journal of Biological Chemistry.

[31]  K. Nakayama,et al.  Involvement of Phospholipase C-Related Inactive Protein in the Mouse Reproductive System Through the Regulation of Gonadotropin Levels1 , 2009, Biology of reproduction.

[32]  Asli Silahtaroglu,et al.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. , 2007, Cancer research.

[33]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[34]  Lei Wang,et al.  Upregulated microRNA-301 a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt / β-catenin signaling ☆ , 2013 .

[35]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .